# Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

> **NCT00344318** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 806 (actual)

## Conditions studied

- Infections, Streptococcal

## Interventions

- **BIOLOGICAL:** Pneumococcal conjugate vaccine GSK1024850A
- **BIOLOGICAL:** Prevenar
- **BIOLOGICAL:** Tritanrix-HepB
- **BIOLOGICAL:** Hiberix
- **BIOLOGICAL:** Polio Sabin.
- **BIOLOGICAL:** Poliorix.

## Key facts

- **NCT ID:** NCT00344318
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-07
- **Primary completion:** 2007-04-27
- **Final completion:** 2007-10-17
- **Target enrollment:** 806 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344318, "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00344318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*